{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:29:42Z","timestamp":1791772182037,"version":"4.3.4"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bcp.2023.115910","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T20:20:24Z","timestamp":1699993224000},"page":"115910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase"],"prefix":"10.1016","volume":"218","author":[{"given":"Patrick","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zukhra","family":"Shaihutdinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Lockridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115910_b0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bcp.2018.01.044","article-title":"Cholinesterases and the fine line between poison and remedy","volume":"153","author":"Pope","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2023.115910_b0015","article-title":"Butyrylcholinesterase in lipid metabolism: A new outlook","author":"Gok","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2023.115910_b0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygcen.2015.05.017","article-title":"Pure human butyrylcholinesterase hydrolyzes octanoyl ghrelin to desacyl ghrelin","volume":"224","author":"Schopfer","year":"2015","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.bcp.2023.115910_b0025","doi-asserted-by":"crossref","first-page":"12012","DOI":"10.1016\/S0021-9258(18)33669-X","article-title":"Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase","volume":"257","author":"Lockridge","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0167-4838(89)90282-3","article-title":"A naturally occurring molecular form of human plasma cholinesterase is an albumin conjugate","volume":"998","author":"Masson","year":"1989","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bcp.2023.115910_b0035","doi-asserted-by":"crossref","first-page":"41141","DOI":"10.1074\/jbc.M210241200","article-title":"Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products","volume":"278","author":"Nicolet","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0040","doi-asserted-by":"crossref","first-page":"13270","DOI":"10.1073\/pnas.1817009115","article-title":"Cryo-EM structure of the native butyrylcholinesterase tetramer reveals a dimer of dimers stabilized by a superhelical assembly","volume":"115","author":"Leung","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2023.115910_b0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.biochi.2018.10.017","article-title":"3D structure of the natural tetrameric form of human butyrylcholinesterase as revealed by cryoEM, SAXS and MD","volume":"156","author":"Boyko","year":"2019","journal-title":"Biochimie."},{"key":"10.1016\/j.bcp.2023.115910_b0050","first-page":"5","article-title":"Polyproline-rich peptides organize four cholinesterase subunits into a tetramer; BChE and AChE Scavenge Polyproline Peptides Released during Metabolic Turnover","volume":"62","author":"Lockridge","year":"2020","journal-title":"Proceedings."},{"key":"10.1016\/j.bcp.2023.115910_b0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.taap.2005.01.046","article-title":"Toxicological implications of esterases - From molecular structures to functions","volume":"207","author":"Satoh","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1359-6446(05)03383-0","article-title":"Mammalian carboxylesterases: from drug targets to protein therapeutics","volume":"10","author":"Redinbo","year":"2005","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.bcp.2023.115910_b0065","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/092986706776360969","article-title":"Carboxylesterases\u2013detoxifying enzymes and targets for drug therapy","volume":"13","author":"Potter","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200219666180821094502","article-title":"The impact of carboxylesterases in drug metabolism and pharmacokinetics","volume":"20","author":"Di","year":"2019","journal-title":"Curr. Drug. Metab."},{"key":"10.1016\/j.bcp.2023.115910_b0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2174\/1381612824666171213102310","article-title":"Substrates for Paraoxonase","volume":"24","author":"Mu","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2023.115910_b0080","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.3390\/ijms241210383","article-title":"Albumin is a component of the esterase status of human blood plasma","volume":"24","author":"Belinskaia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13318-023-00834-8","article-title":"Hydrolytic Metabolism of WithangulatinA Mediated by Serum Albumin Instead of Common Esterases in Plasma","volume":"48","author":"Zhuang","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2023.115910_b0090","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-pharmtox-052220-105907","article-title":"Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development","volume":"62","author":"Fukami","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2023.115910_b0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/prot.26243","article-title":"The protonation state of Glu202 in acetylcholinesterase","volume":"90","author":"Wang","year":"2022","journal-title":"Proteins."},{"key":"10.1016\/j.bcp.2023.115910_b0105","first-page":"34","article-title":"Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses","volume":"148","author":"Lockridge","year":"2015","journal-title":"PharmacolTher."},{"key":"10.1016\/j.bcp.2023.115910_b0110","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1021\/bi962484a","article-title":"Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human Butyrylcholinesterase","volume":"36","author":"Masson","year":"1997","journal-title":"Biochemistry."},{"key":"10.1016\/j.bcp.2023.115910_b0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2044.1980.tb03800.x","article-title":"Plasma cholinesterase variants and the anaesthetist","volume":"35","author":"Whittaker","year":"1980","journal-title":"Anaesthesia."},{"key":"10.1016\/j.bcp.2023.115910_b0120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/anae.14545","article-title":"Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review","volume":"74","author":"Andersson","year":"2019","journal-title":"Anaesthesia."},{"key":"10.1016\/j.bcp.2023.115910_b0125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/cr00081a005","article-title":"Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states","volume":"87","author":"Quinn","year":"1987","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2023.115910_b0130","doi-asserted-by":"crossref","first-page":"11010","DOI":"10.1016\/S0021-9258(18)90614-9","article-title":"Direct determination of acetyl-enzyme intermediate in the acetylcholinesterase-catalyzed hydrolysis of acetylcholine and acetylthiocholine","volume":"259","author":"Froede","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbapap.2006.10.012","article-title":"Hydrolysis of oxo- and thio-esters by human butyrylcholinesterase","volume":"1774","author":"Masson","year":"2007","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bcp.2023.115910_b0140","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bbapap.2007.06.004","article-title":"Kinetic analysis of butyrylcholinesterase-catalyzed hydrolysis of acetanilides","volume":"1774","author":"Masson","year":"2007","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bcp.2023.115910_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10121608","article-title":"1-(3-tert-butylphenyl)-2,2,2-trifluoroethanone as a potent transition-state analogue slow-binding inhibitor of human acetylcholinesterase: Kinetic, MD and QM\/MM Studies","volume":"10","author":"Zueva","year":"2020","journal-title":"Biomolecules."},{"key":"10.1016\/j.bcp.2023.115910_b0150","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1042\/bj1410825","article-title":"A steady-state kinetic model of butyrylcholinesterase from horse plasma","volume":"141","author":"Augustinsson","year":"1974","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2023.115910_b0155","doi-asserted-by":"crossref","first-page":"12074","DOI":"10.1021\/bi00096a018","article-title":"Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors","volume":"32","author":"Radic","year":"1993","journal-title":"Biochemistry."},{"key":"10.1016\/j.bcp.2023.115910_b0160","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.3390\/ijms241310472","article-title":"Activation\/Inhibition of cholinesterases by excess substrate: interpretation of the phenomenological b factor in steady-state rate equation","volume":"24","author":"Mukhametgalieva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0165","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1021\/tx200237a","article-title":"Production of ES1 plasma carboxylesterase knockout mice for toxicity studies","volume":"24","author":"Duysen","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2023.115910_b0170","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.20542","article-title":"Enzymes involved in the bioconversion of ester-based prodrugs","volume":"95","author":"Liederer","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0175","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.1073\/pnas.1706517114","article-title":"Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling","volume":"114","author":"Chen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2023.115910_b0180","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(81)90392-0","article-title":"Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies","volume":"30","author":"Valentino","year":"1981","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0167-4838(98)00104-6","article-title":"Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters","volume":"1387","author":"Masson","year":"1998","journal-title":"Biochim. Biophys. Acta Protein Struct. Mol. Enzymol."},{"key":"10.1016\/j.bcp.2023.115910_b0190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thrombosis Research."},{"key":"10.1016\/j.bcp.2023.115910_b0195","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.3390\/ijms21239049","article-title":"Natural Salicylates and Their Roles in Human Health","volume":"21","author":"Yeasmin","year":"2020","journal-title":"IJMS."},{"key":"10.1016\/j.bcp.2023.115910_b0200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0928-0987(02)00124-0","article-title":"Isosorbide-based aspirin prodrugs","volume":"16","author":"Gilmer","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cbi.2005.10.095","article-title":"Novel isosorbide-based substrates for human butyrylcholinesterase","volume":"157\u2013158","author":"Gilmer","year":"2005","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2023.115910_b0210","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/jm801094c","article-title":"Discovery of a \u201ctrue\u201d aspirin prodrug","volume":"51","author":"Moriarty","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0215","first-page":"35","article-title":"Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine","volume":"47","author":"Lockridge","year":"1990","journal-title":"PharmacolTher."},{"key":"10.1016\/j.bcp.2023.115910_b0220","first-page":"37","article-title":"Studies on the metabolism of benoxinate by human pseudocholinesterase","volume":"7","author":"Dubbels","year":"1983","journal-title":"Metab. Pediatr. Syst. Ophthalmol."},{"key":"10.1016\/j.bcp.2023.115910_b0225","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0024-3205(83)90616-1","article-title":"Evidence from opiate binding studies that heroin acts through its metabolites","volume":"33","author":"Inturrisi","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0230","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bph.12305","article-title":"Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats","volume":"170","author":"Gott\u00e5s","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0235","first-page":"1","article-title":"Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase","volume":"215","author":"Lockridge","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2023.115910_b0240","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/acs.chemrestox.6b00228","article-title":"Naturally occurring genetic variants of human Acetylcholinesterase and Butyrylcholinesterase and their potential impact on the risk of toxicity from cholinesterase inhibitors","volume":"29","author":"Lockridge","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2023.115910_b0245","first-page":"203","article-title":"The relation between dose of succinylcholine and duration of apnea in man","volume":"120","author":"Kalow","year":"1957","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2023.115910_b0250","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF03019096","article-title":"Atypical plasma cholinesterase. A personal discovery story: a tale of three cities","volume":"51","author":"Kalow","year":"2004","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.bcp.2023.115910_b0255","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1073\/pnas.86.3.953","article-title":"Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase","volume":"86","author":"McGuire","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2023.115910_b0260","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1399-6576.1993.tb03721.x","article-title":"Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase","volume":"37","author":"\u00d8stergaard","year":"1993","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.bcp.2023.115910_b0265","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00228-005-0905-x","article-title":"Interaction between mivacurium and pancuronium: impact of the order of administration","volume":"61","author":"Motamed","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0270","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00000542-198810000-00006","article-title":"Clinical pharmacology of doxacurium chloride. A New Long-Acting Nondepolarizing Muscle Relaxant","volume":"69","author":"Basta","year":"1988","journal-title":"Anesthesiology."},{"key":"10.1016\/j.bcp.2023.115910_b0275","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/dmd.109.031724","article-title":"Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide","volume":"38","author":"Albert\u00ed","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2023.115910_b0280","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1021\/ja020850+","article-title":"Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase","volume":"125","author":"Zhan","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2023.115910_b0285","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/acs.bioconjchem.2c00210","article-title":"Development of a highly efficient long-acting cocaine hydrolase entity to accelerate cocaine metabolism","volume":"33","author":"Zheng","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0290","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fphar.2018.00112","article-title":"Treating cocaine addiction, obesity, and emotional disorders by viral gene transfer of butyrylcholinesterase","volume":"9","author":"Brimijoin","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0295","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00210-006-0054-5","article-title":"The presence of atropinesterase activity in animal plasma, NaunynSchmiedebergs","volume":"373","author":"Harrison","year":"2006","journal-title":"Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0300","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/096032718300200409","article-title":"Inhibition of atropine metabolism by organophosphate pesticides","volume":"2","author":"Van Der Meer","year":"1983","journal-title":"Hum. Toxicol."},{"key":"10.1016\/j.bcp.2023.115910_b0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13659-022-00357-w","article-title":"Beauty of the beast: anticholinergic tropane alkaloids in therapeutics","volume":"12","author":"Shim","year":"2022","journal-title":"Nat. Prod. Bioprospect."},{"key":"10.1016\/j.bcp.2023.115910_b0310","first-page":"7","article-title":"Acceleration of the enzymic hydrolysis of benzoylcholine","volume":"11","author":"Fraser","year":"1956","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0315","first-page":"287","article-title":"Allosteric reactions of horse serum cholinesterase","volume":"47","author":"Kamaric","year":"1975","journal-title":"Croat. Chem. Acta."},{"key":"10.1016\/j.bcp.2023.115910_b0320","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/0006-2952(85)90395-8","article-title":"Aprophen: A substrate and inhibitor of butyrylcholinesterase and carboxylesterases","volume":"34","author":"Rush","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0325","first-page":"309","article-title":"Biochemical characterization of flestolol esterase","volume":"81","author":"Quon","year":"1993","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0773.1980.tb02018.x","article-title":"Plasma induced biotransformation of thymoxamine and its kinetics","volume":"47","author":"Nielsen-Kudsk","year":"1980","journal-title":"Acta Pharmacol. Toxicol. (copenh)"},{"key":"10.1016\/j.bcp.2023.115910_b0335","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0928-0987(98)00058-X","article-title":"In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man","volume":"8","author":"Ericsson","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0340","first-page":"279","article-title":"Hydrolysis of methylprednisolone acetate by human serum cholinesterase","volume":"10","author":"Meyers","year":"1982","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2023.115910_b0345","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.bcp.2007.01.031","article-title":"The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue","volume":"73","author":"Mutch","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0350","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.00500-06","article-title":"Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases","volume":"50","author":"Lindegardh","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2023.115910_b0355","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.3390\/molecules25092156","article-title":"Tricyclic derivative of acyclovir and its esters in relation to the esters of acyclovir enzymatic stability: enzymatic stability study","volume":"25","author":"Muszalska-Kolos","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.bcp.2023.115910_b0360","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.3390\/ijms24032849","article-title":"Evaluation of in vitro distribution and plasma protein binding of selected antiviral drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2","volume":"24","author":"D\u00f6m\u00f6t\u00f6r","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0365","first-page":"1458","article-title":"The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase","volume":"59","author":"Morton","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2023.115910_b0370","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bcp.2010.09.001","article-title":"Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11","volume":"81","author":"Hatfield","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115910_b0375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cbi.2005.10.016","article-title":"The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase","volume":"157\u2013158","author":"Harel","year":"2005","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2023.115910_b0380","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1248\/jhs.53.60","article-title":"Butyrylcholinesterase and erythrocyte sulfhydryl-dependent enzyme hydrolyze Gabexate in human blood","volume":"53","author":"Yamaori","year":"2007","journal-title":"J. Health Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0385","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jps.2600840525","article-title":"Comparison of enzymatic hydrolysis of pilocarpine prodrugs in human plasma, rabbit cornea, and Butyrylcholinesterase solutions","volume":"84","author":"J\u00e4rvinen","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0390","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000267220","article-title":"Characterization of esterases involved in the hydrolysis of dipivefrin hydrochloride","volume":"25","author":"Nakamura","year":"1993","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.bcp.2023.115910_b0395","first-page":"328","article-title":"Cicatricial Entropion Associated With Chronic Dipivefrin Application: Ophthalmic Plast","volume":"17","author":"D\u2019Ostroph","year":"2001","journal-title":"Reconstr. Surg."},{"key":"10.1016\/j.bcp.2023.115910_b0400","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/js9700558","article-title":"Metabolic Deesterification of Tazarotene in Human Blood and Rat and HumanLiver Microsomes","volume":"86","author":"Madhu","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0405","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1021\/js980358h","article-title":"Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs","volume":"88","author":"Udata","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115910_b0410","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0009-9236(95)90072-1","article-title":"Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics","volume":"58","author":"Cutler","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2023.115910_b0415","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1042\/bst0220758","article-title":"Trimethylsilylated trifluoromethyl ketones, a novel class of acetylcholinesterase inhibitors: biochemical and pharmacological profile of MDL 73,745","volume":"22","author":"Hornsperger","year":"1994","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2023.115910_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109558","article-title":"Protective effects of m-(tert-butyl) trifluoroacetophenone, a transition state analogue of acetylcholine, against paraoxon toxicity and memory impairments","volume":"345","author":"Zueva","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2023.115910_b0425","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of Myasthenia Gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2023.115910_b0430","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jat.3662","article-title":"Reversible cholinesterase inhibitors as pretreatment for exposure to organophosphates. A review","volume":"39","author":"Lorke","year":"2019","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.bcp.2023.115910_b0435","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.neubiorev.2016.10.017","article-title":"Pretreatment and prophylaxis against nerve agent poisoning: Are undesirable behavioral side effects unavoidable?","volume":"71","author":"Myhrer","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bcp.2023.115910_b0440","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/mi.10.1.1","article-title":"Episodes in the story of physostigmine","volume":"10","author":"Scheindlin","year":"2010","journal-title":"Mol. Interv."},{"key":"10.1016\/j.bcp.2023.115910_b0445","first-page":"367","article-title":"Physostigmine\u2013an overview as pretreatment drug for organophosphate intoxication","volume":"27","author":"Somani","year":"1989","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.bcp.2023.115910_b0450","first-page":"199","article-title":"Mechanism of eserine action on the hydrolysis of butyrylthiocholine by butyrylcholinesterase","volume":"11","author":"Stojan","year":"1997","journal-title":"J. Enzyme. Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0455","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ab.2007.09.023","article-title":"Microcalorimetric study of the inhibition of butyrylcholinesterase by carbamates","volume":"373","author":"Debord","year":"2008","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bcp.2023.115910_b0460","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1021\/bi020016x","article-title":"Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine","volume":"41","author":"Bar-On","year":"2002","journal-title":"Biochemistry."},{"key":"10.1016\/j.bcp.2023.115910_b0465","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2165\/00003088-199631040-00002","article-title":"Clinical pharmacokinetics of bambuterol","volume":"31","author":"Sitar","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2023.115910_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113059","article-title":"Pleiotropic prodrugs: design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer\u2019s disease","volume":"210","author":"Toublet","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0475","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3109\/02713681003794076","article-title":"Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma","volume":"35","author":"Schmidt","year":"2010","journal-title":"Curr. Eye. Res."},{"key":"10.1016\/j.bcp.2023.115910_b0480","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00002093-200304000-00011","article-title":"Inhibition of Human Cholinesterases by Drugs Used to Treat Alzheimer Disease","volume":"17","author":"Darvesh","year":"2003","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.bcp.2023.115910_b0485","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3109\/00498254.2012.675095","article-title":"Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective \u03b23 - adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica."},{"key":"10.1016\/j.bcp.2023.115910_b0490","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41598-018-20464-4","article-title":"Metabolic Hydrolysis of Aromatic Amides in Selected Rat, Minipig, and Human In Vitro Systems","volume":"8","author":"Bradshaw","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2023.115910_b0495","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s11095-023-03530-z","article-title":"Characterization of Divergent Metabolic Pathways in Elucidating an Unexpected, Slow-Forming, and Long Half-Life Major Metabolite of Iclepertin","volume":"40","author":"Chan","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2023.115910_b0500","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/14756360410001667300","article-title":"Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline","volume":"19","author":"Kovarik","year":"2004","journal-title":"J. Enzyme. Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115910_b0505","doi-asserted-by":"crossref","first-page":"e0268292","DOI":"10.1371\/journal.pone.0268292","article-title":"Suillin: a mixed-type acetylcholinesterase inhibitor from Suillus luteus which is used by Saraguros indigenous, southern Ecuador","volume":"17","author":"Andrade","year":"2022","journal-title":"PLoS One."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:08:59Z","timestamp":1731028139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223005038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":101,"alternative-id":["S0006295223005038"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115910","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115910"}}